Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]NNC112
- Development stage
- Phase 1
- Lead developer
- Karolinska Institutet
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]NNC112 is a positron emission tomography (PET) radioligand used for in vivo imaging of dopamine D1 receptors in the human brain. It is synthesized by radiolabeling the D1-selective dopamine receptor antagonist NNC112 with Carbon-11, allowing for the quantitative assessment of D1 receptor binding, especially in the striatum and cortex. Although originally thought to be highly selective for D1 receptors, later studies showed some affinity for serotonin 5-HT2A receptors in cortical regions. Its main application is in research studies of neuropsychiatric disorders, including schizophrenia, Parkinson's disease, substance use disorders, and other conditions involving dopaminergic function.[1][2][3][7][9]
- Other names
- (+)-[11C]NNC112Carbon-11-NNC112Carbon11-NNC112Carbon 11-NNC1128-chloro-7-hydroxy-3-methyl-5-(7-benzofuranyl)-2,3,4,5-tetrahydro-1H-3-benzazepine (labeled with Carbon-11)
02
Targets
HTR2A (Serotonin receptor 5-HT2A)DRD1 (Dopamine D1 Receptor)
Beyond the preview
Go deeper on [11C]NNC112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]NNC112.